Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to -$6.1 million.

  • Xeris Biopharma Holdings' Non Operating Income rose 95.64% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.4 million, marking a year-over-year decrease of 2440.47%. This contributed to the annual value of -$23.5 million for FY2024, which is 2033.45% down from last year.
  • Xeris Biopharma Holdings' Non Operating Income amounted to -$6.1 million in Q3 2025, which was up 95.64% from -$6.4 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Non Operating Income ranged from a high of $1.9 million in Q4 2022 and a low of -$7.6 million during Q3 2023
  • For the 5-year period, Xeris Biopharma Holdings' Non Operating Income averaged around -$4.4 million, with its median value being -$4.5 million (2023).
  • Examining YoY changes over the last 5 years, Xeris Biopharma Holdings' Non Operating Income showed a top increase of 17550.62% in 2022 and a maximum decrease of 34027.78% in 2022.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Non Operating Income stood at -$2.5 million in 2021, then surged by 175.51% to $1.9 million in 2022, then plummeted by 299.0% to -$3.8 million in 2023, then tumbled by 79.45% to -$6.8 million in 2024, then increased by 10.04% to -$6.1 million in 2025.
  • Its Non Operating Income stands at -$6.1 million for Q3 2025, versus -$6.4 million for Q2 2025 and -$6.1 million for Q1 2025.